Recent evidence suggests that CD86 may have prognostic value in CLL, particularly in predicting time to first treatment and potential resistance to targeted therapies such as ibrutinib and venetoclax [37,38]. The gene discussed is CD86; the disease is B-cell chronic lymphocytic leukemia.